OPKO Health Responds to Law Firm Notice of Investigation

August 23, 2016 12:47pm EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NYSE:OPK) , is aware of a press release by

Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it

is investigating the Company for an alleged potential breach of

fiduciary duty claim involving the Company’s Board of Directors. The

Company has not received any notification or information from Purcell

Julie & Lefkowitz regarding its investigation of any potential breach of

fiduciary duty or other claim against OPKO’s Board of Directors. Nor

have any such claims or allegations been made by any shareholders, other

law firms or regulatory bodies. OPKO’s attempts to contact the law firm

have gone unanswered. The Company does not believe there is any basis or

merit behind the investigation and will vigorously defend itself should

any formal allegations or claims be made.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes Bio-Reference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore prostate cancer test and the Claros

1 in-office immunoassay platform. Our pharmaceutical business

features RAYALDEE , an FDA approved treatment for SHPT in stage

3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for

chemotherapy-induced nausea and vomiting (oral formulation launched by

partner Tesaro and IV formulation PDUFA is January 2017). Our biologics

business includes hGH-CTP, a once-weekly human growth hormone injection

(in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug

for hemophilia (in Phase 2a) and a long acting oxyntomodulin for

diabetes and obesity (in Phase 1). We also have production and

distribution assets worldwide, multiple strategic investments and an

active business development strategy. More information is available at www.opko.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that

term is defined under the Private Securities Litigation Reform Act of

1995 (PSLRA), which statements may be identified by words such as

"expects," "plans," "projects," "will," "may," "anticipates,"

"believes," "should," "intends," "estimates," and other words of similar

meaning, including statements regarding whether a formal investigation

or legal proceeding will be commenced against OPKO, as well as other

non-historical statements about our expectations, beliefs or intentions

regarding our business, technologies and products, financial condition,

strategies or prospects. Many factors could cause our actual activities

or results to differ materially from the activities and results

anticipated in forward-looking statements. These factors include those

described in our Annual Reports on Form 10-K filed and to be filed with

the Securities and Exchange Commission and in our other filings with the

Securities and Exchange Commission. The forward-looking statements

contained in this press release speak only as of the date the statements

were made, and we do not undertake any obligation to update

forward-looking statements. We intend that all forward-looking

statements be subject to the safe-harbor provisions of the PSLRA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160823006090/en/

Company

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor

Relations

or

Media

Rooney & Associates

Terry

Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

or

Investors

LHA

Anne

Marie Fields, 212-838-3777

or

Bruce

Voss, 310-691-7100

Source: OPKO Health, Inc.

Released August 23, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap